Mylan

Mylan is a global pharmaceutical company that develops, licenses, manufactures, markets, and distributes a wide range of generic drugs and branded drugs. Mylan was founded in 1961 by Don Panoz and Milan Panić and is headquartered in Canonsburg, Pennsylvania, with operations in over 165 countries, including Australia, Canada, China, Europe, India, Japan, and the United States. Mylan has a diverse portfolio of products, including EpiPen, Perforomist, and Dymista, which are used to treat various medical conditions, such as allergies, asthma, and chronic obstructive pulmonary disease (COPD) at hospitals like Johns Hopkins Hospital and Massachusetts General Hospital. Mylan has partnerships with other companies, including Pfizer, GSK, and AstraZeneca, to develop and market new products, such as Prevnar 13 and Symbicort.

● History

Mylan was founded in 1961 by Don Panoz and Milan Panić as a small pharmaceutical company in White Sulphur Springs, West Virginia. In the 1970s, Mylan began to expand its operations, establishing a manufacturing facility in Morgantown, West Virginia and acquiring several other pharmaceutical companies, including Bertek Pharmaceuticals and Matrix Laboratories. In the 1990s, Mylan went public with an initial public offering (IPO) on the NASDAQ stock exchange, raising capital to further expand its operations and develop new products, such as EpiPen, which was approved by the US Food and Drug Administration (FDA) in 1987. Mylan has since acquired several other companies, including King Pharmaceuticals and Meda Pharmaceuticals, and has established partnerships with other companies, such as Pfizer and GSK, to develop and market new products, including Prevnar 13 and Symbicort, which are used to treat pneumococcal disease and COPD at hospitals like Cleveland Clinic and University of California, San Francisco (UCSF).

● Products

Mylan has a diverse portfolio of products, including generic drugs and branded drugs, which are used to treat a wide range of medical conditions, such as allergies, asthma, and COPD. Some of Mylan's most well-known products include EpiPen, a auto-injector used to treat anaphylaxis, and Perforomist, a bronchodilator used to treat COPD. Mylan also markets several other products, including Dymista, a nasal spray used to treat allergic rhinitis, and Wixela Inhub, a generic version of GlaxoSmithKline's Advair Diskus, which is used to treat asthma and COPD at hospitals like Mayo Clinic and Duke University Hospital. Mylan has partnerships with other companies, including Pfizer and AstraZeneca, to develop and market new products, such as Prevnar 13 and Symbicort, which are used to treat pneumococcal disease and COPD.

● Corporate Affairs

Mylan is a global company with operations in over 165 countries, including Australia, Canada, China, Europe, India, Japan, and the United States. The company is headquartered in Canonsburg, Pennsylvania, and has manufacturing facilities in several countries, including Ireland, India, and the United States. Mylan has a diverse workforce of over 35,000 employees, including research and development (R&D) scientists, manufacturing personnel, and sales and marketing professionals, who work with hospitals like NewYork-Presbyterian Hospital and University of Pennsylvania Health System. Mylan has partnerships with other companies, including Pfizer, GSK, and AstraZeneca, to develop and market new products, such as Prevnar 13 and Symbicort, which are used to treat pneumococcal disease and COPD at research institutions like National Institutes of Health (NIH) and Harvard University.

● Controversies

Mylan has been involved in several controversies over the years, including criticism over the high price of its EpiPen product, which has been the subject of several US Congressional hearings, including those held by the US Senate Committee on Health, Education, Labor and Pensions and the US House Committee on Oversight and Government Reform. Mylan has also faced criticism over its tax inversion deal with AbbVie, which was announced in 2015, and has been the subject of several lawsuits, including those filed by shareholders and consumers, which have been heard in courts like the US District Court for the Southern District of New York and the US Court of Appeals for the Third Circuit. Mylan has also been criticized for its lobbying activities, including its efforts to influence US healthcare policy, which have been reported by news organizations like The New York Times and The Washington Post.

● Financials

Mylan is a publicly traded company listed on the NASDAQ stock exchange, with a market capitalization of over $10 billion. The company generates revenue from the sale of its products, including generic drugs and branded drugs, which are used to treat a wide range of medical conditions, such as allergies, asthma, and COPD. Mylan's revenue has grown significantly over the years, driven by the acquisition of several other companies, including King Pharmaceuticals and Meda Pharmaceuticals, and the launch of new products, such as Wixela Inhub, a generic version of GlaxoSmithKline's Advair Diskus. Mylan has also established partnerships with other companies, including Pfizer and AstraZeneca, to develop and market new products, such as Prevnar 13 and Symbicort, which are used to treat pneumococcal disease and COPD at hospitals like Stanford Health Care and University of Chicago Medical Center.

Category:Pharmaceutical companies